Tumor Lysis Syndrome and Oncologic Emergencies

Tumor lysis syndrome (TLS) is an oncologic emergency in which the rapid breakdown of tumour cells — often triggered by effective treatment — floods the circulation with intracellular contents, producing dangerous metabolic derangements. It is the prototype of the oncologic emergencies, acute complications of cancer or its therapy that require prompt recognition.

Definition

Tumor lysis syndrome is a metabolic emergency caused by the rapid lysis of malignant cells, characterized by hyperuricaemia, hyperkalaemia, hyperphosphataemia, and secondary hypocalcaemia, which can lead to acute kidney injury, cardiac arrhythmia, and seizures.

Scope

This topic covers the pathophysiology, defining metabolic abnormalities, and risk context of tumor lysis syndrome, and frames it within the broader category of oncologic emergencies. It describes how the syndrome arises and is classified; it is reference material and does not provide prophylaxis, monitoring schedules, or treatment instructions.

Core questions

• What metabolic abnormalities define tumor lysis syndrome?
• Why does effective cancer treatment sometimes precipitate it?
• Which tumours and patient factors raise the risk?
• How is laboratory TLS distinguished from clinical TLS?

Key concepts

• Rapid tumour-cell lysis
• Hyperuricaemia
• Hyperkalaemia
• Hyperphosphataemia
• Secondary hypocalcaemia
• Acute kidney injury
• Cairo-Bishop laboratory vs clinical TLS classification
• High tumour burden and high proliferative rate as risk factors
• Oncologic emergencies

Mechanisms

When large numbers of tumour cells die rapidly — frequently soon after cytotoxic therapy in highly proliferative, bulky malignancies — they release potassium, phosphate, and nucleic acids into the blood faster than the kidneys can clear them. Nucleic-acid breakdown generates uric acid, causing hyperuricaemia; released phosphate causes hyperphosphataemia and, by complexing calcium, secondary hypocalcaemia; and released potassium causes hyperkalaemia. Uric-acid and calcium-phosphate precipitation in the renal tubules, together with the electrolyte shifts, can produce acute kidney injury, cardiac arrhythmias, and seizures. The Cairo-Bishop framework distinguishes laboratory TLS, defined by the metabolic abnormalities alone, from clinical TLS, in which organ complications occur.

Clinical relevance

Tumor lysis syndrome illustrates why anticancer treatment itself can precipitate a life-threatening emergency, and recognizing the at-risk setting is part of safe oncologic and acute-care practice. This entry describes the syndrome and its classification as educational reference; it is not a guide to prophylaxis, monitoring, or treatment.

Epidemiology

The syndrome is most associated with haematologic malignancies that have a high tumour burden and rapid cell turnover, such as acute leukaemias and high-grade lymphomas, particularly when these are highly responsive to chemotherapy; it can also occur, less commonly, with bulky chemosensitive solid tumours.

History

Tumor lysis syndrome was recognized as treatment of chemosensitive haematologic cancers intensified, when clinicians observed acute metabolic crises following effective therapy. The Cairo and Bishop (2004) definition standardized its classification into laboratory and clinical forms, and subsequent reviews consolidated understanding of its pathophysiology and risk stratification within the framework of oncologic emergencies.

Key figures

• Mitchell S. Cairo
• Scott C. Howard
• Ching-Hon Pui

Seminal works

• cairo-2004
• howard-2011

Frequently asked questions

Why can cancer treatment trigger tumor lysis syndrome?

Effective therapy can kill a large mass of tumour cells very quickly, releasing their intracellular contents — potassium, phosphate, and uric-acid precursors — into the blood faster than the body can clear them, producing the syndrome's metabolic abnormalities.

What is the difference between laboratory and clinical tumor lysis syndrome?

Laboratory tumor lysis syndrome is defined by the characteristic blood abnormalities alone, whereas clinical tumor lysis syndrome additionally involves organ complications such as acute kidney injury, cardiac arrhythmia, or seizures.